TABLE 1.
Activity of grazoprevir in HCV GT4 subtypes
| Replicon (GenBank accession no.)a | Mean EC (nM) ± SDb |
|
|---|---|---|
| EC50 | EC90 | |
| Group 1 | ||
| GT4a ED43 (GU814265) | 0.7 ± 0.4 | 1.4 ± 0.7 |
| GT4b (FJ025854) | 0.17 ± 0.04 | 0.27 ± 0.05 |
| GT4b (FJ025855) | 0.11 ± 0.04 | 0.32 ± 0.13 |
| GT4g (JX227963) | 0.15 ± 0.09 | 0.71 ± 0.78 |
| GT4g (JX227971) | 0.33 ± 0.1 | 0.6 ± 0.16 |
| Group 2 | ||
| GT4a ED43 (GU814265) | 3.7 ± 1.3 | 9 ± 3.33 |
| GT4d (DQ418786) | 1.1 ± 0.8 | 4.8 ± 1.4 |
| GT4o (JX227977) | 1.2 ± 0.6 | 2.8 ± 0.1 |
a
For group 1, chimeric replicons bearing patient isolates were generated in a GT2a_JFH1 background, and potencies were determined using a TaqMan-based assay. For group 2, the GT4 NS3 subtype sequences are in a full-length ED43 background with the G162R adaptive mutation and were assayed by monitoring the luciferase activity.
b
Potencies were determined by using a TaqMan-based assay (group 1) or luciferase assay (group 2).